The Food and Drug Administration's intimation to Eli Lilly & Co. in late January that the regulator wouldn't approve Lilly's serotonin and norepinephrine reuptake inhibitor (SNRI) duloxetine as a treatment for stress urinary incontinence (SUI) could be a setback for more than just Lilly and partner Boehringer Ingelheim GMBH . [See Deal]
The FDA move surprised observers, particularly considering the lack of existing pharmacotherapy for SUI and duloxetine's safety profile, which have...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)